An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Gemcitabine
Related studies linked through entity extraction aliases.
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
- Status
- RECRUITING
- Phase
- PHASE3
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2